Literature DB >> 1666894

Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro.

J S Nixon1, K M Bottomley, M J Broadhurst, P A Brown, W H Johnson, G Lawton, J Marley, A D Sedgwick, S E Wilkinson.   

Abstract

The matrix metalloproteinases (MMPs) collagenase, gelatinase and stromelysin, contribute to the destruction of articular cartilage which occurs during rheumatoid and osteoarthritis. Ro 31-4724, a substrate analogue containing a hydroxamic acid function, is a potent but non-selective inhibitor of all three MMPs (I50, collagenase = 10 nM), whereas Ro 31-7467, a phosphinic acid transition-state analogue, shows 14-fold and 12-fold selectivity for collagenase (I50 = 17 nM) over gelatinase and caseinase (stromelysin) respectively. The effects of these inhibitors on interleukin-1-induced bovine nasal cartilage degradation were examined. The hydroxamate Ro 31-4724 inhibits proteoglycan and collagen loss, whereas the phosphinic acid Ro 31-7467 selectively inhibits collagen breakdown in this model. This represents the first demonstration of potent and selective inhibition of IL1-induced cartilage degradation in vitro by MMP inhibitors. These results suggest that collagenase is responsible for collagen loss and that a different enzyme, possibly stromelysin, is responsible for proteoglycan degradation in this model.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666894

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  18 in total

1.  Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation.

Authors:  K M Southgate; M Davies; R F Booth; A C Newby
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

2.  Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

Authors:  D J Buttle; H Bramwell; A P Hollander
Journal:  Clin Mol Pathol       Date:  1995-08

3.  Selective and non-selective metalloproteinase inhibitors reduce IL-1-induced cartilage degradation and loss of mechanical properties.

Authors:  Christopher G Wilson; Ashley W Palmer; Fengrong Zuo; Elsie Eugui; Stacy Wilson; Rebecca Mackenzie; John D Sandy; Marc E Levenston
Journal:  Matrix Biol       Date:  2006-11-11       Impact factor: 11.583

Review 4.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  "Aggrecanase" activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay.

Authors:  D J Buttle; A Fowles; M Z Ilic; C J Handley
Journal:  Mol Pathol       Date:  1997-06

6.  3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.

Authors: 
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

7.  Metalloprotease inhibitors halt collagen breakdown in IL-1 induced bovine nasal cartilage cultures.

Authors:  S Spirito; J Doughty; E O'Byrne; V Ganu; R L Goldberg
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

8.  Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.

Authors:  K M Bottomley; N Borkakoti; D Bradshaw; P A Brown; M J Broadhurst; J M Budd; L Elliott; P Eyers; T J Hallam; B K Handa; C H Hill; M James; H W Lahm; G Lawton; J E Merritt; J S Nixon; U Röthlisberger; A Whittle; W H Johnson
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

9.  Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

Authors:  R L Van Bezooijen; L Van Der Wee-Pals; S E Papapoulos; C W G M Löwik
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 10.  Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.

Authors:  J Thomas Peterson
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.